Q-omics provides the consensus-scored KCNJ3 profile across patient tissues and cancer cell-line models. KCNJ3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCNJ3 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, KCNJ3 RNA expression shows 17,861 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where KCNJ3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNJ3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNJ3 survival associations across molecular data types. KCNJ3 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNJ3 RNA expression–survival associations across cancer types. High KCNJ3 expression shows unfavorable associations in UVM, ESCA and UCEC, but favorable associations in KIRC, BRCA and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCNJ3 RNA expression.
This table summarizes KCNJ3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for KCNJ3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNJ3 shows lower tumor expression in KICH, BLCA, KIRP, KIRC and UCEC and higher tumor expression in BRCA. The KICH box plot shows higher KCNJ3 RNA expression in normal versus tumor tissue (log2 FC = −4.050, t-test p < 0.001).
This table shows molecular features associated with KCNJ3 in patient tissues and cancer cell lines. In patient samples, KCNJ3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNJ3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
